Readiness to quit as a predictor for outcomes of smoking-reduction programme with transdermal nicotine patch or bupropion in a sample of 308 patients with schizophrenia

European Archives of Psychiatry and Clinical Neuroscience

Volumn 265, Issue 3, 2015, Pages 249-257

  Chou, Kuan Ju ^a   Chen, Hsing Kang ^a   Hung, Chih Hung ^b   Chen, Tzu Ting ^c   Chen, Chun Ming ^d   Wu, Bo Jian ^a  

^a Yuli Hospital   (Taiwan)

^b Ping An Hospital   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Readiness to quit; Schizophrenia; Smoking cessation; Smoking reduction; Stage of change; Taiwan

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; NICOTINE GUM; NICOTINIC AGENT;

ADULT; COMPLICATION; FEMALE; HUMAN; MALE; MIDDLE AGED; NONPARAMETRIC TEST; PROCEDURES; PSYCHOLOGY; READING; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SMOKING; SMOKING CESSATION; TAIWAN;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; READING; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SMOKING; SMOKING CESSATION; STATISTICS, NONPARAMETRIC; TAIWAN; TOBACCO USE CESSATION PRODUCTS;

EID: 84939876058     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-014-0515-7     Document Type: Article

References (50)

1. Lyon ER (1999) A review of the effects of nicotine on schizophrenia and antipsychotic medications. Psychiatr Serv 50(10):1346–1350
2. Beratis S, Katrivanou A, Gourzis P (2001) Factors affecting smoking in schizophrenia. Compr Psychiatry 42(5):393–402
3. Leonard S, Adler LE, Benhammou K, Berger R, Breese CR, Drebing C, Gault J, Lee MJ, Logel J, Olincy A, Ross RG, Stevens K, Sullivan B, Vianzon R, Virnich DE, Waldo M, Walton K, Freedman R (2001) Smoking and mental illness. Pharmacol Biochem Behav 70(4):561–570
4. Corrigall WA (1991) Understanding brain mechanisms in nicotine reinforcement. Br J Addict 86(5):507–510
5. Silagy C, Mant D, Fowler G, Lancaster T (2000) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2
6. Baker A, Richmond R, Haile M, Lewin TJ, Carr VJ, Taylor RL, Jansons S, Wilhelm K (2006) A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry 163(11):1934–1942
7. George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR (2000) Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 157(11):1835–1842
8. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340(9):685–691
9. Evins AE, Cather C, Rigotti NA, Freudenreich O, Henderson DC, Olm-Shipman CM, Goff DC (2004) Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry 65(3):307–311
10. Lucksted A, Dixon LB, Sembly JB (2000) A focus group pilot study of tobacco smoking among psychosocial rehabilitation clients. Psychiatr Serv 51(12):1544–1548
11. Ziedonis DM, George TP (1997) Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 23(2):247–254
12. Addington J, El-Guebaly N, Campbell W, Hodgins DC, Addington D (1998) Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry 155(7):974–976
13. Chou KR, Chen R, Lee JF, Ku CH, Lu RB (2004) The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Int J Nurs Stud 41(3):321–330
14. George TP, Vessicchio JC, Sacco KA, Weinberger AH, Dudas MM, Allen TM, Creeden CL, Potenza MN, Feingold A, Jatlow PI (2008) A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry 63(11):1092–1096
15. Prochaska JO, DiClemente CC (1983) Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol 51(3):390–395
16. DiClemente CC, Prochaska JO, Fairhurst SK, Velicer WF, Velasquez MM, Rossi JS (1991) The process of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of change. J Consult Clin Psychol 59(2):295–304
17. Velicer WF, Norman GJ, Fava JL, Prochaska JO (1999) Testing 40 predictions from the transtheoretical model. Addict Behav 24(4):455–469
18. Sutton S (2001) Back to the drawing board? A review of applications of the transtheoretical model to substance use. Addiction 96(1):175–186
19. Strecher VJ, Shiffman S, West R (2005) Randomized controlled trial of a web-based computer-tailored smoking cessation program as a supplement to nicotine patch therapy. Addiction 100(5):682–688
20. Prochaska JO, DiClemente CC, Norcross JC (1992) In search of how people change. Applications to addictive behaviors. Am Psychol 47(9):1102–1114
21. Abrams DB, Herzog TA, Emmons KM, Linnan L (2000) Stages of change versus addiction: a replication and extension. Nicotine Tob Res 2(3):223–229
22. Dino G, Kamal K, Horn K, Kalsekar I, Fernandes A (2004) Stage of change and smoking cessation outcomes among adolescents. Addict Behav 29(5):935–940
23. Perz C, DiClemente C, Carbonari J (1996) Doing the right thing at the right time? The interaction of stages and processes of change in successful smoking cessation. Health Psychol 15(6):462–468
24. Bolliger CT (2000) Practical experiences in smoking reduction and cessation. Addiction 95(1):S19–S24
25. Hughes JR, Carpenter MJ (2005) The feasibility of smoking reduction: an update. Addiction 100(8):1074–1089
26. Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A, Perruchoud AP, Sawe U (2002) Influence of long-term smoking reduction on health risk markers and quality of life. Nicotine Tob Res 4(4):433–439
27. Falba T, Jofre-Bonet M, Busch S, Duchovny N, Sindelar J (2004) Reduction of quantity smoked predicts future cessation among older smokers. Addiction 99(1):93–102
28. Etter M, Mohr S, Garin C, Etter JF (2004) Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population. Schizophr Bull 30(2):459–468
29. Esterberg ML, Compton MT (2005) Smoking behavior in persons with a schizophrenia-spectrum disorder: a qualitative investigation of the transtheoretical model. Soc Sci Med 61(2):293–303
30. Godtfredsen NS, Prescott E, Osler M, Vestbo J (2001) Predictors of smoking reduction and cessation in a cohort of Danish moderate and heavy smokers. Preventive Med 33(1):46–52
31. Wu BJ, Chen HK, Lee SM (2013) Do atypical antipsychotics really enhance smoking reduction more than typical ones? The effects of antipsychotics on smoking reduction in patients with schizophrenia. J Clin Psychopharmacol 33(3):319–328
32. Cheng JJ, Ho H, Chang CJ, Lan SY, Hwu HG (1996) Positive and Negative Syndrome Scale (PANSS): establishment and reliability study of a Mandarin Chinese language version. Taiwan J Psychiatry 10:251–258
33. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276
34. Simpson G, Kunz-Bartholini E (1968) Relationship of individual tolerance, behavior and phenothiazine produced extrapyramidal system disturbance. Dis Nerv Syst 29(4):269–274
35. Huang CL, Lin HH, Wang HH (2006) The psychometric properties of the Chinese version of the Fagerstrom test for nicotine dependence. Addict Behav 31(12):2324–2327
36. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO (1991) The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86(9):1119–1127
37. Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167(6):686–693
38. Chen HK, Lan TH, Wu BJ (2013) A double-blind randomized clinical trial of different doses of transdermal nicotine patch for smoking reduction and cessation in long-term hospitalized schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 263(1):75–82
39. Ong KC, Cheong GN, Prabhakaran L, Earnest A (2005) Predictors of success in smoking cessation among hospitalized patients. Respirology 10(1):63–69
40. Evins AE, Mays VK, Rigotti NA, Tisdale T, Cather C, Goff DC (2001) A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res 3(4):397–403
41. Lan TH, Chiu HJ, Wu BJ, Hung TH, Hu TM (2007) Readiness to quit and smoking reduction outcomes. Am J Psychiatry 164(5):827–828
42. Bohadana A, Nilsson F, Rasmussen T, Martinet Y (2000) Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 160(20):3128–3134
43. Fredrickson PA, Hurt RD, Lee GM, Wingender L, Croghan IT, Lauger G, Gomez-Dahl L, Offord KP (1995) High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels. Psychopharmacology 122(3):215–222
44. Hurt RD, Dale LC, Fredrickson PA, Caldwell CC, Lee GA, Offord KP, Lauger GG, Marusic Z, Neese LW, Lundberg TG (1994) Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement [see comment]. JAMA 271(8):595–600
45. Evins AE, Culhane MA, Alpert JE, Pava J, Liese BS, Farabaugh A, Fava M (2008) A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. J Clin Psychopharmacol 28(6):660–666
46. Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, Henderson DC, Schoenfeld DA, Goff DC, Rigotti NA (2005) A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 25(3):218–225
47. Liao DL, Yang JY, Lee SM, Chen H, Tsai SJ (2002) Smoking in chronic schizophrenic inpatients in taiwan. Neuropsychobiology 45(4):172–175
48. Addington J (1998) Group treatment for smoking cessation among persons with schizophrenia. Psychiatr Serv 49(7):925–928
49. McChargue DE, Gulliver SB, Hitsman B (2002) Would smokers with schizophrenia benefit from a more flexible approach to smoking treatment? Addiction 97(7):785–793
50. Oshima I, Mino Y, Inomata Y (2007) How many long-stay schizophrenia patients can be discharged in Japan? Psychiatry Clin Neurosci 61(1):71–77